Emergent BioSolutions Inc. announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and be completed by March 2026.
This new contract modification is the latest step in Emergent's ongoing engagement with the U.S. government, aiming to ensure medical countermeasures like CYFENDUS vaccine are readily available to safeguard civilian populations against anthrax. Emergent highlights its U.S.-based supply chain as critical to its leadership in supporting national security priorities.
CYFENDUS was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use. This award follows a previously announced $50 million contract modification for CYFENDUS in December 2024, further bolstering anthrax preparedness efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.